Summary
Using flurbiprofen, a chiral anti-inflammatory and analgesic 2-arylpropionic acid derivative, the enantiomers of which are not converted to each other (less than 5%) in rats or man, we obtained evidence that prostaglandin synthesis inhibition is primarily mediating the anti-inflammatory activity but prostaglandin synthesis independent mechanisms contribute to the analgesic effects. Thus, the S-form inhibited prostaglandin synthesis, inflammation and nociception in rats. The R-form had much less effect on prostaglandin synthesis and did not affect inflammation. It did, however, block nociception in rats almost as potently as the S-form. S-flurbiprofen, in contrast to the R-form, was clearly ulcerogenic in the gastrointestinal mucosa. These results indicate additional molecular mechanisms of analgesia and suggest the use of R-arylpropionic acids as analgesics.
Similar content being viewed by others
References
Vane, J. R., Nature231 (1971) 232.
Ferreira, S. H., Moncada, S., and Vane, J. R., Nature231 (1971) 237.
Brune, K., Agents Actions4 (1974) 230.
Brune, K., and Lanz, R., in: Handbook of Inflammation, vol. 5, p. 413. Eds I. L. Bonta, M. A. Bray and M. J. Parnham. Elsevier, Amsterdam 1985.
Higgs, G. A., Salmon, J. A., Henderson, B., and Vane, J. R., Proc. natl Acad. Sci. USA84 (1987) 1417.
McCormack, K., and Brune, K., Drugs (1991) in press.
Brune, K., Rainsford, K. D., Wagner, K., and Peskar, B. A., Naunyn-Schmiedeberg's Arch. Pharmac315 (1981) 269.
Lanz, R., Polster, P., and Brune, K., Eur. J. Pharmac.130 (1986) 105.
Rosenkranz, B., Fischer, C., Meese, C. O. and Frolich, J. C., Br. J. clin. Pharmac.21(1986) 309.
Williams, K. M., Pharmac. Ther.46 (1990) 273.
Adams, S. S., Bresloff, P., and Mason, C. G., J. Pharm. Pharmac.28 (1976) 256.
Geisslinger, G., Schuster, O., Stock, K. P., Loew, D., Bach, G. L., and Brune, K., Eur. J. clin. Pharmac.38 (1990) 493.
Jamali, F., Mehvar, R., and Pasutto, F. M., J. pharm. Sci.78 (1989) 695.
Caldwell, J., Hutt, A. J., and Fournel-Gigleux, S., Biochem. Pharmac.37 (1988) 105.
Berry, B. W., and Jamali, F., Pharm. Res.5 (1988) 123.
Menzel-Soglowek, S., Geisslinger, G., and Brune, K., J. Chromat.532 (1990) 295.
Nakamura, Y., Yamaguchi, T., Takahashi, S., Hashimoto, S., Iwatani, D., and Nakagawa, Y., J. Pharmacobiodyn.4 (1981) 1.
Williams, K. M., Day, R. O., Knihinicki, R., and Duffield, A., Biochem. Pharmac.35 (1986) 3403.
Shearman, M. S., Sekiguchi, K., and Nishizuka, Y., Pharmac. Rev.41 (1989) 211.
Ferreira, S. H., Lorenzetti, B. B., and Correa, F. M. A., Eur. J. Pharmac.53 (1978) 39.
Jurna, J., and Brune, K., Pain41 (1990) 71.
Adams, S. S., McCullough, K. F., and Nicholson, J. S., Drug. Res.25 (1975) 1786.
Vane, J. R., Drugs33 (1987) 18.
Preston, S. J., Arnold, M. H., Beller, E. M. Brooks, P. M., and Buchanan, W. W., Br. J. clin. Pharmac.27 (1989) 607.
Sedgwick, A. D., and Lees, P., Agents Actions18 (1986) 429.
Sedgwick, A. D., and Lees, P., Agents Actions18 (1986) 439.
Peskar, B. M., Hoppe, U., Lange, K., and Peskar, B. A., Br. J. Pharmac.93 (1988) 937.
Winter, C. A., Risley, E. A., and Nuss, G. W., Proc. Soc. exp. Biol. Med.111 (1962) 544.
Randall, L. O., and Selitto, J. J., Archs int. Pharmacodyn.111 (1957) 409.
Ferreira, S. H., Lorenzetti, B. B., Bristow, A. F., and Poole, S., Nature334 (1988) 698.
Beck, W. S., Schneider, H. T., Dietzel, K., Nuernberg, B., and Brune, K., Archs Toxic.64 (1990) 210.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brune, K., Beck, W.S., Geisslinger, G. et al. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 47, 257–261 (1991). https://doi.org/10.1007/BF01958153
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01958153